These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
339 related articles for article (PubMed ID: 20035676)
1. [Radiolabeled antibodies for cancer treatment]. Barbet J; Chatal JF; Kraeber-Bodéré F Med Sci (Paris); 2009 Dec; 25(12):1039-45. PubMed ID: 20035676 [TBL] [Abstract][Full Text] [Related]
2. Perspectives on cancer therapy with radiolabeled monoclonal antibodies. Sharkey RM; Goldenberg DM J Nucl Med; 2005 Jan; 46 Suppl 1():115S-27S. PubMed ID: 15653660 [TBL] [Abstract][Full Text] [Related]
3. Improving the delivery of radionuclides for imaging and therapy of cancer using pretargeting methods. Sharkey RM; Karacay H; Cardillo TM; Chang CH; McBride WJ; Rossi EA; Horak ID; Goldenberg DM Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7109s-7121s. PubMed ID: 16203810 [TBL] [Abstract][Full Text] [Related]
4. Different ways to improve the clinical effectiveness of radioimmunotherapy in solid tumors. Chatal JF; Davodeau F; Cherel M; Barbet J J Cancer Res Ther; 2009 Sep; 5 Suppl 1():S36-40. PubMed ID: 20009292 [TBL] [Abstract][Full Text] [Related]
5. Current status and perspectives in alpha radioimmunotherapy. Chérel M; Davodeau F; Kraeber-Bodéré F; Chatal JF Q J Nucl Med Mol Imaging; 2006 Dec; 50(4):322-9. PubMed ID: 17043629 [TBL] [Abstract][Full Text] [Related]
6. Benefits of combined radioimmunotherapy and anti-angiogenic therapy in a liver metastasis model of human colon cancer cells. Li XF; Kinuya S; Yokoyama K; Koshida K; Mori H; Shiba K; Watanabe N; Shuke N; Michigishi T; Tonami N Eur J Nucl Med Mol Imaging; 2002 Dec; 29(12):1669-74. PubMed ID: 12458402 [TBL] [Abstract][Full Text] [Related]
10. Comparison of different classes of radionuclides for potential use in radioimmunotherapy. Karagiannis TC Hell J Nucl Med; 2007; 10(2):82-8. PubMed ID: 17684582 [TBL] [Abstract][Full Text] [Related]
11. Development of a streptavidin-anti-carcinoembryonic antigen antibody, radiolabeled biotin pretargeting method for radioimmunotherapy of colorectal cancer. Studies in a human colon cancer xenograft model. Sharkey RM; Karacay H; Griffiths GL; Behr TM; Blumenthal RD; Mattes MJ; Hansen HJ; Goldenberg DM Bioconjug Chem; 1997; 8(4):595-604. PubMed ID: 9258460 [TBL] [Abstract][Full Text] [Related]
12. Principles of radioimmunotherapy for hematologists and oncologists. Press OW; Rasey J Semin Oncol; 2000 Dec; 27(6 Suppl 12):62-73. PubMed ID: 11226002 [TBL] [Abstract][Full Text] [Related]
13. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model. Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986 [TBL] [Abstract][Full Text] [Related]
14. Radioimmunotherapy of experimental human metastatic melanoma with melanin-binding antibodies and in combination with dacarbazine. Revskaya E; Jongco AM; Sellers RS; Howell RC; Koba W; Guimaraes AJ; Nosanchuk JD; Casadevall A; Dadachova E Clin Cancer Res; 2009 Apr; 15(7):2373-9. PubMed ID: 19293257 [TBL] [Abstract][Full Text] [Related]
17. Development of a streptavidin-anti-carcinoembryonic antigen antibody, radiolabeled biotin pretargeting method for radioimmunotherapy of colorectal cancer. Reagent development. Karacay H; Sharkey RM; Govindan SV; McBride WJ; Goldenberg DM; Hansen HJ; Griffiths GL Bioconjug Chem; 1997; 8(4):585-94. PubMed ID: 9258459 [TBL] [Abstract][Full Text] [Related]
18. A Phase I study of combined modality (90)Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer. Alvarez RD; Huh WK; Khazaeli MB; Meredith RF; Partridge EE; Kilgore LC; Grizzle WE; Shen S; Austin JM; Barnes MN; Carey D; Schlom J; LoBuglio AF Clin Cancer Res; 2002 Sep; 8(9):2806-11. PubMed ID: 12231520 [TBL] [Abstract][Full Text] [Related]
19. A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer. Wong JY; Shibata S; Williams LE; Kwok CS; Liu A; Chu DZ; Yamauchi DM; Wilczynski S; Ikle DN; Wu AM; Yazaki PJ; Shively JE; Doroshow JH; Raubitschek AA Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5842-52. PubMed ID: 14676105 [TBL] [Abstract][Full Text] [Related]
20. Status of radioimmunotherapy in the new millennium. Imam SK Cancer Biother Radiopharm; 2001 Jun; 16(3):237-56. PubMed ID: 11471488 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]